Lonza completes Capsugel acquisition for $5.5 billion

By Stephen Daniells

- Last updated on GMT

© iStock/Kritchanut
© iStock/Kritchanut
Switzerland’s Lonza has completed the acquisition of Capsugel S.A. from KKR after receiving all the required regulatory approvals.

The acquisition aligns with Lonza’s strategy to accelerate its growth and ability to deliver value along the healthcare continuum, said the company in a release.

“Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration,” ​said Richard Ridinger, Lonza's CEO.

The $5.5 billion transaction price includes approximately $2 billion for refinancing of existing Capsugel debt. Capsugel’s business will continue to operate in its existing structure until the full integration has been completed, said Lonza.

Acquisition trail

Last year, Lonza acquired Benicia, CA-based InterHealth Nutraceuticals,​ a nutritional ingredient research, development, and manufacture company, for $300 million.

InterHealth’s flagship ingredient is UC-II for join-health, although the company offers more than 15 branded ingredients.

Related news

Show more

Related products

show more

PlexoZome®: Genuine Liposomal Delivery Technology

PlexoZome®: Genuine Liposomal Delivery Technology

Content provided by Gencor | 06-Nov-2023 | White Paper

This White Paper looks at PlexoZome®, a scientifically proven complex liposomal technology. These genuine liposomes are verified through TEM & Cryo-TEM...

The Art of Organic Certification

The Art of Organic Certification

Content provided by FoodChain ID | 23-Oct-2023 | White Paper

The organic food market has experienced remarkable growth over the past decade, providing a major opportunity for food brands and manufacturers to tap...

Related suppliers

Follow us

Products

View more

Webinars